Endocytosis is a complex process whereby cell surface proteins, lipids and fluid from the
extracellular environment are packaged, sorted and internalized into cells. Endocytosis is …

KRAS is the most frequently mutated oncogene, harboring mutations in approximately one
in seven cancers. Allele-specific KRASG12C inhibitors are currently changing the treatment …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …

Molecular dynamics (MD) simulations have become increasingly useful in the modern drug
development process. In this review, we give a broad overview of the current application …

KRAS is the most frequently mutated driver of pancreatic, colorectal, and non–small cell lung
cancers. Direct KRAS blockade has proved challenging, and inhibition of a key downstream …

How the KRAS oncogene drives cancer growth remains poorly understood. Therefore, we
established a systemwide portrait of KRAS-and extracellular signal–regulated kinase (ERK) …

Oncogenic mutations in KRAS drive common metabolic programmes that facilitate tumour
survival, growth and immune evasion in colorectal carcinoma, non-small-cell lung cancer …

Our understanding of how the RAS protein family, and in particular mutant KRAS, promotes
metabolic dysregulation in cancer cells has advanced substantially over the last decade. In …

KRAS mutations are one of the most common oncogenic drivers in human cancer. While
small molecule inhibitors for the G12C mutant have been successfully developed, allele …

Pancreatic cancer is a recalcitrant cancer with one of the lowest 5-year survival rates. A
hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene …